Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02848274 · ClinicalTrials.gov registry record
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
A clinical trial of Non-Hodgkin's Lymphoma and Mycosis Fungoides, sponsored by Stanford University.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 13
- Study locations
NCT02848274 is a study of Non-Hodgkin's Lymphoma and Mycosis Fungoides that is actively recruiting participants, run by Stanford University. The registered enrollment target is 2,000 participants, above the 190-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (953% higher). The trial reports 13 study locations across 7 states.
The verdict
NCT02848274, a study of Non-Hodgkin's Lymphoma and Mycosis Fungoides, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.
Conditions Studied
Study Locations (13)
Other
- Hospital Italiano de Buenos Aires - Buenos Aires
- Peter MacCallum Cancer Center, - Melbourne
- University of Sao Paulo Medical School - São Paulo
- Peking University First Hospital - Beijing
- The University of Tokyo - Tokyo
- University Hospitals Birmingham - Birmingham
California
- City of Hope - Duarte
- Stanford University, School of Medicine - Palo Alto
Iowa
- University of Iowa - Iowa City
New Jersey
- Hackensack University Medical Center - Hackensack
Pennsylvania
- University of Pittsburg - Pittsburgh
Texas
- University of Texas Southwestern - Dallas
Utah
- University of Utah Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2016-10 |
| Est. Completion | 2027-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02848274
The ClinicalTrials.gov registry entry for NCT02848274 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 190-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (953% higher). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT02848274 reports 13 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Iowa.
Frequently Asked Questions
What is clinical trial NCT02848274 about?
NCT02848274 is a clinical study titled "ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome". The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups f...
What is the current status of trial NCT02848274?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2016-10. Estimated completion is 2027-03.
What conditions does trial NCT02848274 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, Mycosis Fungoides.
Who is sponsoring clinical trial NCT02848274?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02848274 being conducted?
This trial has 13 study locations across California, Iowa, New Jersey, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
RECRUITING
-
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
RECRUITING
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.